SPOA strongly deactivates BCR-ABL1 Y177, preventing GRB2 binding and blocking proliferation, as well as inducing apoptosis in even IM-resistant CML cells [169]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.